Novo Nordisk A/S (NVO), once the undisputed king of the global weight-loss drug market, has seen its market value plummet more than 60% over the past two years, significantly lagging broader equity benchmarks. But 2026 has brought a tentative rebound, with shares rallying sharply over the past month following better-than-feared first-quarter results and groundbreaking clinical data for its high-dose Wegovy treatment presented at the European Congress on Obesity. Investors are now asking: Is this a fleeting bounce, or the start of a genuine turnaround?
Novo Nordisk’s dramatic stock decline stemmed from two existential threats: fierce competition from Eli Lilly and Co.’s Zepbound, which captured market share with superior weight-loss efficacy, and looming patent expirations for semaglutide in Canada, India, and China, where multiple drugmakers plan to launch generic versions. The market had broadly written off the Danish pharma giant, concluding it had lost its dominant position in the fast-growing obesity treatment space and faced dim growth prospects.
That narrative began to shift on May 6, when Novo Nordisk released its first-quarter earnings. On the surface, the results were underwhelming: adjusted net sales fell 10% year-over-year to 70.1 billion Danish kroner ($11 billion), while adjusted earnings per share dropped 3% to 6.63 DKK ($1.03). However, these figures were fully in line with the company’s previously issued full-year guidance and significantly better than the market’s most pessimistic forecasts. The upside surprise was driven entirely by oral Wegovy, launched in January, which has already been prescribed to more than 2 million patients thanks to its convenience advantage over injectable alternatives.
Just as investors were digesting the earnings beat, Novo Nordisk delivered another catalyst at the 2026 European Congress on Obesity in Istanbul: pivotal data from its STEP UP trial for high-dose Wegovy (7.2mg).
The results showed that early responders – patients who lost at least 15% of their body weight in the first 24 weeks of treatment – achieved an average weight loss of 27.7% at week 72 on the 7.2mg dose, compared to 24.8% for those on the standard 2.4mg dose. Across all trial participants, the high-dose formulation delivered 20.7% average weight loss, versus 17.5% for the standard dose. Critically, the study also confirmed that Wegovy effectively preserves muscle mass: 84% of weight lost was fat, with muscle mass declining only 10% from baseline, and patients maintained consistent muscular strength. This addresses a major industry concern about unintended muscle loss associated with GLP-1 class drugs.
Novo Nordisk now has a two-pronged growth strategy centered on oral Wegovy and injectable Wegovy HD, which has already won approval in the UK, US, EU, and Brazil this year. The company also boasts a deep pipeline of next-generation treatments: CagriSema, its dual-acting obesity and diabetes drug, is awaiting regulatory approval; Amycretin, a dual-target GLP-1/amylin agonist, is in clinical development; and UBT251, a triple-target hormone mimetic, posted outstanding phase 2 results in China. Analysts expect multiple pipeline catalysts over the next 12 months.
Despite the recent rally, Novo Nordisk remains attractively valued at 13.6x forward earnings, a significant discount to the healthcare sector average of 16.8x. Market participants acknowledge that while current financial results justify a lower multiple, continued pipeline progress could drive sustained share price appreciation even before new products deliver meaningful revenue growth, making the stock compelling for medium-term investors.
Still, significant challenges remain. Eli Lilly’s Zepbound continues to pressure market share, semaglutide patent expirations will erode revenue in key emerging markets, and rivals including Roche, Pfizer, and Boehringer Ingelheim are racing to launch their own weight-loss treatments.
In conclusion, Novo Nordisk’s recent rebound is not a speculative bubble but is grounded in tangible fundamental improvements: stronger-than-expected oral Wegovy adoption, transformative high-dose clinical data, and a robust late-stage pipeline. However, it is too early to declare a full turnaround. The company’s ability to sustain its momentum will depend on maintaining sales traction for its existing products and successfully advancing its next-generation treatments through clinical development and regulatory approval.
